Sarepta Therapeutics Stock Price, News & Analysis (NASDAQ:SRPT)

$56.11 1.07 (1.94 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$56.11
Today's Range$56.30 - $54.75
52-Week Range$26.26 - $57.57
Volume1.52 million shs
Average Volume2.34 million shs
Market Capitalization$3.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:SRPT
  • Previous Symbol: NASDAQ:AVII
  • CUSIP: N/A
  • Web: www.sarepta.com
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 10.44%
  • Quick Ratio: 9.52%
Sales & Book Value:
  • Annual Sales: $5.42 million
  • Price / Sales: 669.08
  • Book Value: $10.79 per share
  • Price / Book: 5.20
Profitability:
  • Trailing EPS: ($2.04)
  • Net Income: ($267,260,000.00)
  • Net Margins: -112.08%
  • Return on Equity: -51.72%
  • Return on Assets: -43.55%
Misc:
  • Employees: 197
  • Outstanding Shares: 64,630,000
 

Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:SRPT)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.66. The biotechnology company had revenue of $45.95 million for the quarter, compared to analysts' expectations of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. View Sarepta Therapeutics' Earnings History.

Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2017?

19 brokers have issued 1-year price objectives for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $101.00. On average, they expect Sarepta Therapeutics' stock price to reach $65.61 in the next year. View Analyst Ratings for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sarepta beat estimates for both earnings and sales in the third quarter and raised its 2017 sales outlook. Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year." (10/30/2017)
  • 2. Cowen and Company analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
  • 3. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
  • 4. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
  • 5. Royal Bank Of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:

  • Douglas S. Ingram, President, Chief Executive Officer (Age 54)
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
  • Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
  • Richard J. Barry, Independent Director (Age 58)
  • M. Kathleen Behrens Ph.D., Independent Director (Age 64)
  • Claude Nicaise M.D., Independent Director (Age 64)
  • Hans Wigzell M.D., Ph.D., Independent Director (Age 79)

Who owns Sarepta Therapeutics stock?

Sarepta Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (2.55%), Jennison Associates LLC (1.77%), Eagle Asset Management Inc. (1.56%), Emerald Advisers Inc. PA (1.39%), Emerald Mutual Fund Advisers Trust (1.11%) and Elk Creek Partners LLC (1.11%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Asymmetry Capital Management L.P., Artal Group S.A., Pictet Asset Management Ltd., Granite Point Capital Management L.P. and Pinnacle Associates Ltd.. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.

Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Alyeska Investment Group L.P., Gilder Gagnon Howe & Co. LLC, TimesSquare Capital Management LLC, Oak Ridge Investments LLC, Eagle Asset Management Inc., Elk Creek Partners LLC and Chartwell Investment Partners LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram and M Kathleen Behrens. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $56.11.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $3.56 billion and generates $5.42 million in revenue each year. The biotechnology company earns ($267,260,000.00) in net income (profit) each year or ($2.04) on an earnings per share basis. Sarepta Therapeutics employs 197 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 1st St Ste 415, CAMBRIDGE, MA 02142-1213, United States. The biotechnology company can be reached via phone at +1-617-2744000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  823 (Vote Outperform)
Underperform Votes:  522 (Vote Underperform)
Total Votes:  1,345
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sarepta Therapeutics (NASDAQ:SRPT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 15 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $65.61 (16.93% upside)

Consensus Price Target History for Sarepta Therapeutics (NASDAQ:SRPT)

Price Target History for Sarepta Therapeutics (NASDAQ:SRPT)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Needham & Company LLCReiterated RatingBuyN/AView Rating Details
10/26/2017Barclays PLCBoost Price TargetEqual Weight$46.00 -> $49.00N/AView Rating Details
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
10/17/2017Robert W. BairdReiterated RatingBuy$101.00N/AView Rating Details
10/16/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$76.00N/AView Rating Details
10/6/2017The Goldman Sachs Group, Inc.Reiterated RatingBuy -> Buy$71.00N/AView Rating Details
10/3/2017Royal Bank Of CanadaReiterated RatingBuy$64.00LowView Rating Details
10/2/2017William BlairReiterated RatingOutperformLowView Rating Details
10/2/2017InstinetReiterated RatingBuy$84.00LowView Rating Details
10/2/2017Credit Suisse GroupReiterated RatingOutperform$81.00LowView Rating Details
10/2/2017Morgan StanleyUpgradeEqual Weight -> Overweight$60.00HighView Rating Details
9/30/2017Leerink SwannReiterated RatingOutperform$66.00HighView Rating Details
9/25/2017J P Morgan Chase & CoReiterated RatingHoldLowView Rating Details
9/14/2017Cowen and CompanyReiterated RatingOutperform$69.00MediumView Rating Details
9/7/2017SunTrust Banks, Inc.Reiterated RatingBuy$56.00HighView Rating Details
9/5/2017NomuraReiterated RatingBuy$84.00LowView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$65.00 -> $73.00HighView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingHold$27.00MediumView Rating Details
3/1/2017JMP SecuritiesLower Price Target$48.00N/AView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00N/AView Rating Details
5/5/2016Ladenburg Thalmann Financial ServicesDowngradeMarket Perform -> Underperform$13.00 -> $5.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Sarepta Therapeutics (NASDAQ:SRPT)

Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Earnings History by Quarter for Sarepta Therapeutics (NASDAQ SRPT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017Q3 2017($0.86)($0.20)$41.29 million$45.95 millionViewN/AView Earnings Details
7/19/2017Q2 2017($0.92)($0.46)$22.52 million$35.01 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
2017 EPS Consensus Estimate: ($2.37)
2018 EPS Consensus Estimate: ($1.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176($1.15)$0.57($0.65)
Q2 20176($1.02)$1.22($0.26)
Q3 20176($1.17)($0.78)($0.94)
Q4 20176($0.97)($0.21)($0.52)
Q1 20182($0.43)($0.16)($0.30)
Q2 20182($0.49)($0.08)($0.29)
Q3 20182($0.34)($0.14)($0.24)
Q4 20182($0.22)($0.20)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sarepta Therapeutics (NASDAQ SRPT)

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 67.76%
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ SRPT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2017Douglas S IngramCEOBuy38,138$52.44$1,999,956.72View SEC Filing  
11/6/2017Shamim RuffSVPSell10,000$55.00$550,000.00View SEC Filing  
10/3/2017Shamim RuffSVPSell11,500$50.00$575,000.00View SEC Filing  
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00View SEC Filing  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.86View SEC Filing  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.00View SEC Filing  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.00View SEC Filing  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.00View SEC Filing  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.00View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.00View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sarepta Therapeutics (NASDAQ:SRPT)

Latest Headlines for Sarepta Therapeutics (NASDAQ SRPT)

Source:
DateHeadline
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas S. Ingram Acquires 38,138 SharesSarepta Therapeutics, Inc. (SRPT) CEO Douglas S. Ingram Acquires 38,138 Shares
www.americanbankingnews.com - November 13 at 5:15 PM
Sarepta Therapeutics Announces Exercise of Initial Purchasers Option to Purchase Additional Convertible Senior ... - GlobeNewswire (press release)Sarepta Therapeutics Announces Exercise of Initial Purchasers' Option to Purchase Additional Convertible Senior ... - GlobeNewswire (press release)
globenewswire.com - November 11 at 2:02 PM
Sarepta Therapeutics Will Continue To Ride High On EXONDYS 51s Success In 2017 - Seeking AlphaSarepta Therapeutics Will Continue To Ride High On EXONDYS 51's Success In 2017 - Seeking Alpha
seekingalpha.com - November 9 at 7:03 PM
Sarepta Therapeutics - Insider Buying And What The Capital Raise Means - Seeking AlphaSarepta Therapeutics - Insider Buying And What The Capital Raise Means - Seeking Alpha
seekingalpha.com - November 9 at 7:03 PM
Sarepta Therapeutics (SRPT) to Offer $375M of Convertible Senior NotesSarepta Therapeutics (SRPT) to Offer $375M of Convertible Senior Notes
www.streetinsider.com - November 9 at 2:02 PM
-$0.40 Earnings Per Share Expected for Sarepta Therapeutics, Inc. (SRPT) This Quarter-$0.40 Earnings Per Share Expected for Sarepta Therapeutics, Inc. (SRPT) This Quarter
www.americanbankingnews.com - November 9 at 11:40 AM
Insider Selling: Sarepta Therapeutics, Inc. (SRPT) SVP Sells 10,000 Shares of StockInsider Selling: Sarepta Therapeutics, Inc. (SRPT) SVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - November 8 at 9:22 PM
Research Analysts Set Expectations for Sarepta Therapeutics, Inc.s FY2017 Earnings (SRPT)Research Analysts Set Expectations for Sarepta Therapeutics, Inc.'s FY2017 Earnings (SRPT)
www.americanbankingnews.com - November 8 at 10:36 AM
Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program - William Blair - StreetInsider.comSarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program - William Blair - StreetInsider.com
www.streetinsider.com - November 6 at 7:16 AM
Sarepta Therapeutics (SRPT), Nationwide Childrens Hospital Announce FDA Clearance of IND Application for ... - StreetInsider.comSarepta Therapeutics (SRPT), Nationwide Children's Hospital Announce FDA Clearance of IND Application for ... - StreetInsider.com
www.streetinsider.com - November 4 at 10:10 PM
Sarepta Therapeutics (SRPT), Nationwide Childrens Hospital Announce FDA Clearance of IND Application for GALGT2 Gene Therapy ProgramSarepta Therapeutics (SRPT), Nationwide Children's Hospital Announce FDA Clearance of IND Application for GALGT2 Gene Therapy Program
www.streetinsider.com - November 4 at 5:07 PM
Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy ProgramSarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program
finance.yahoo.com - November 4 at 5:07 PM
Sarepta Takes Another Big Step Forward With DMD TreatmentSarepta Takes Another Big Step Forward With DMD Treatment
finance.yahoo.com - November 4 at 5:07 PM
Verastem (VSTM) & Sarepta Therapeutics (SRPT) Head to Head ContrastVerastem (VSTM) & Sarepta Therapeutics (SRPT) Head to Head Contrast
www.americanbankingnews.com - November 4 at 5:12 AM
Sarepta Therapeutics Expects Robust Revenue Growth for 2017Sarepta Therapeutics Expects Robust Revenue Growth for 2017
finance.yahoo.com - November 2 at 9:16 AM
Comparing Sarepta Therapeutics (SRPT) and The CompetitionComparing Sarepta Therapeutics (SRPT) and The Competition
www.americanbankingnews.com - November 1 at 11:11 AM
Sarepta Therapeutics Looks To Continue Earnings BeatsSarepta Therapeutics Looks To Continue Earnings Beats
seekingalpha.com - November 1 at 9:11 AM
Sarepta Therapeutics (SRPT) Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR ... - StreetInsider.comSarepta Therapeutics (SRPT) Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR ... - StreetInsider.com
www.streetinsider.com - October 31 at 9:59 AM
Sarepta Therapeutics, Inc. (SRPT) Raised to Buy at Zacks Investment ResearchSarepta Therapeutics, Inc. (SRPT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - October 30 at 12:46 PM
Q4 2017 Earnings Estimate for Sarepta Therapeutics, Inc. (SRPT) Issued By SunTrust BanksQ4 2017 Earnings Estimate for Sarepta Therapeutics, Inc. (SRPT) Issued By SunTrust Banks
www.americanbankingnews.com - October 30 at 6:08 AM
FY2017 EPS Estimates for Sarepta Therapeutics Inc (SRPT) Increased by AnalystFY2017 EPS Estimates for Sarepta Therapeutics Inc (SRPT) Increased by Analyst
www.americanbankingnews.com - October 30 at 2:34 AM
FY2017 Earnings Estimate for Sarepta Therapeutics Inc (SRPT) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Sarepta Therapeutics Inc (SRPT) Issued By Oppenheimer Holdings
www.americanbankingnews.com - October 30 at 2:34 AM
Edited Transcript of SRPT earnings conference call or presentation 25-Oct-17 8:30pm GMTEdited Transcript of SRPT earnings conference call or presentation 25-Oct-17 8:30pm GMT
finance.yahoo.com - October 28 at 7:09 AM
Sarepta: Beat and Raise…Again?Sarepta: Beat and Raise…Again?
finance.yahoo.com - October 28 at 7:09 AM
They Are Seeing Benefits: Sarepta CEO Discusses Success of Rare Disease Drug'They Are Seeing Benefits': Sarepta CEO Discusses Success of Rare Disease Drug
finance.yahoo.com - October 28 at 7:09 AM
Research Analysts Offer Predictions for Sarepta Therapeutics, Inc.s Q3 2018 Earnings (SRPT)Research Analysts Offer Predictions for Sarepta Therapeutics, Inc.'s Q3 2018 Earnings (SRPT)
www.americanbankingnews.com - October 27 at 4:52 PM
Sarepta Therapeutics, Inc. (SRPT) Price Target Raised to $49.00 at Barclays PLCSarepta Therapeutics, Inc. (SRPT) Price Target Raised to $49.00 at Barclays PLC
www.americanbankingnews.com - October 26 at 9:58 PM
Sarepta Therapeutics, Inc. (SRPT) Announces Quarterly  Earnings Results, Beats Expectations By $0.66 EPSSarepta Therapeutics, Inc. (SRPT) Announces Quarterly Earnings Results, Beats Expectations By $0.66 EPS
www.americanbankingnews.com - October 25 at 9:20 PM
Sarepta Therapeutics, Inc. (SRPT) Given Consensus Recommendation of "Buy" by BrokeragesSarepta Therapeutics, Inc. (SRPT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 25 at 4:30 PM
Sarepta Therapeutics beats by $0.65, beats on revenueSarepta Therapeutics beats by $0.65, beats on revenue
seekingalpha.com - October 25 at 4:18 PM
Zacks: Analysts Expect Sarepta Therapeutics, Inc. (SRPT) to Announce -$0.86 EPSZacks: Analysts Expect Sarepta Therapeutics, Inc. (SRPT) to Announce -$0.86 EPS
www.americanbankingnews.com - October 20 at 4:24 PM
Sarepta Therapeutics to Announce Third Quarter 2017 Financial Results and ...Sarepta Therapeutics to Announce Third Quarter 2017 Financial Results and ...
www.nasdaq.com - October 18 at 8:55 AM
Sarepta Therapeutics, Inc. (SRPT) to Release Earnings on WednesdaySarepta Therapeutics, Inc. (SRPT) to Release Earnings on Wednesday
www.americanbankingnews.com - October 18 at 4:06 AM
Sarepta Therapeutics, Inc. (SRPT) Receives "Buy" Rating from Robert W. BairdSarepta Therapeutics, Inc. (SRPT) Receives "Buy" Rating from Robert W. Baird
www.americanbankingnews.com - October 17 at 7:40 PM
Being Careful With Sarepta Here - Seeking AlphaBeing Careful With Sarepta Here - Seeking Alpha
seekingalpha.com - October 17 at 7:37 AM
Sarepta Therapeutics, Inc. (SRPT) Receives "Buy" Rating from Oppenheimer Holdings, Inc.Sarepta Therapeutics, Inc. (SRPT) Receives "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 16 at 4:46 PM
Sarepta Therapeutics, Inc. (SRPT) Short Interest Down 25.7% in SeptemberSarepta Therapeutics, Inc. (SRPT) Short Interest Down 25.7% in September
www.americanbankingnews.com - October 13 at 1:58 AM
SunTrust Banks Weighs in on Sarepta Therapeutics, Inc.s Q4 2017 Earnings (SRPT)SunTrust Banks Weighs in on Sarepta Therapeutics, Inc.'s Q4 2017 Earnings (SRPT)
www.americanbankingnews.com - October 12 at 10:28 AM
Sarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by Goldman Sachs Group, Inc. (The)Sarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 7 at 12:58 AM
Sarepta Therapeutics, Inc. (SRPT) SVP Sells $575,000.00 in StockSarepta Therapeutics, Inc. (SRPT) SVP Sells $575,000.00 in Stock
www.americanbankingnews.com - October 5 at 10:28 PM
What Caused Sarepta Therapeutics to Rally 12.6% in SeptemberWhat Caused Sarepta Therapeutics to Rally 12.6% in September
www.fool.com - October 4 at 7:46 PM
Sarepta Therapeutics: Catalysts With Partnered Programs Loom - Seeking AlphaSarepta Therapeutics: Catalysts With Partnered Programs Loom - Seeking Alpha
seekingalpha.com - October 3 at 12:51 PM
Sarepta Therapeutics shares surge 7.5% after Morgan Stanley upgrade - MarketWatchSarepta Therapeutics shares surge 7.5% after Morgan Stanley upgrade - MarketWatch
www.marketwatch.com - October 3 at 12:51 PM
Todays Research Reports on Trending Tickers: Sarepta Therapeutics and Endo InternationalToday's Research Reports on Trending Tickers: Sarepta Therapeutics and Endo International
finance.yahoo.com - October 3 at 12:51 PM
Sarepta Therapeutics Inc (SRPT) Expected to Announce Quarterly Sales of $37.86 MillionSarepta Therapeutics Inc (SRPT) Expected to Announce Quarterly Sales of $37.86 Million
www.americanbankingnews.com - October 3 at 3:52 AM
Sarepta Therapeutics Stock Soars Despite Adverse Event WorriesSarepta Therapeutics Stock Soars Despite Adverse Event Worries
www.fool.com - October 2 at 3:24 PM
Credit Suisse Group Reiterates Outperform Rating for Sarepta Therapeutics, Inc. (SRPT)Credit Suisse Group Reiterates Outperform Rating for Sarepta Therapeutics, Inc. (SRPT)
www.americanbankingnews.com - October 2 at 2:36 PM
Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by William BlairSarepta Therapeutics, Inc. (SRPT) Rating Reiterated by William Blair
www.americanbankingnews.com - October 2 at 2:36 PM
Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by InstinetSarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Instinet
www.americanbankingnews.com - October 2 at 2:36 PM
Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Robert W. BairdSarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - October 2 at 1:20 PM

Social Media

Financials

Chart

Sarepta Therapeutics (NASDAQ SRPT) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.